Savara, Inc. (SVRA)

[lux1]

last PR about molgradex , 2 case reports
"Both of our patients had a long history of M. abscessus infection that we had not been successful in treating, and both were experiencing a decline in their clinical condition, but when started on inhaled GM-CSF treatment, both demonstrated rapid microbiological response and clinical improvement."

The PR gives us insight that also other lung infections could be treated with Molgarex especially in combo with antibiotics.

http://savarapharma.com/investors/press-releases/release/?id=2330507


Target $35+